国家医保局：进一步加强药品“阴阳价格”监测处置；纽瑞特医疗完成约8亿元D轮融资

Group 1 - The National Healthcare Security Administration (NHSA) has issued a notice to strengthen the monitoring and handling of "dual pricing" practices in retail pharmacies, which discriminate against insured patients, potentially leading to price fraud and increased medication costs [2][3] - The NHSA's measures include self-inspection, multi-departmental verification, and inclusion in surprise inspections, aiming to ensure fairness in healthcare insurance [2] Group 2 - BGI Genomics has licensed its core sequencing technology, CoolMPS, to Swiss biotech company Swiss Rockets for a total amount of at least $120 million, granting exclusive rights for development, production, registration, and commercialization outside of China [2][3] - This licensing agreement is expected to generate significant cash flow and stable long-term revenue for BGI Genomics while reducing compliance and registration risks during international expansion [3] Group 3 - Kangtai Medical received a warning letter from the FDA regarding non-compliance of its medical devices exported to the U.S., which could significantly impact its operations in the American market, accounting for nearly 20% of its revenue [4] - The warning letter may lead to a temporary ban on products in the U.S., and if rectification takes over six months, it could pressure revenue and result in loss of customers [4] Group 4 - Novo Nordisk has decided to terminate all research in cell therapy, affecting its potential "curative" project for type 1 diabetes and leading to layoffs of nearly 250 employees in that department [5] - This decision is part of a restructuring plan aimed at achieving annual cost savings of approximately $1.3 billion by the end of 2026, with a total of 9,000 employees expected to be laid off globally [5] Group 5 - Chengdu Nureter Medical has completed a D-round financing of approximately 800 million RMB, led by Shenzhen Capital Group and PICC Capital, with participation from several well-known investment firms [6] - The funding is expected to accelerate the advancement of four clinical pipelines, particularly aiding the Phase III trial of liver cancer drug NRT6003, despite the global nuclear medicine market being dominated by leading companies [6][7]